Thermo Fisher Scientific Showcases New Solutions and Expanded Capabilities to Accelerate Drug Development at CPHI Milan 2026

Impact · against what's priced in

The announcement of OSD Express and expanded capabilities is not a catalyst for TMO, as it aligns with the recovery and expansion strategies the market has already priced in. These incremental service offerings are insufficient to bridge the gap to the 16.5% revenue CAGR required by the current valuation.

TMO+0.05

Already priced in

The price assumes

A recovery in Pharma and Biotech end markets